Journal
MOLECULAR PHARMACEUTICS
Volume 4, Issue 5, Pages 652-658Publisher
AMER CHEMICAL SOC
DOI: 10.1021/mp0700514
Keywords
targeted therapy; cytotoxic peptide analogues; AN-152 [AEZS 108]; AN-207; AN238; AN-215; LHRH; somatostatin; bombesin
Ask authors/readers for more resources
Gynecological cancers such as breast, ovarian, and endometrial carcinoma express receptors for luteinizing hormone-releasing hormone (LHRH), bombesin/gastrin-releasing peptide (BN/GRP), and somatostatin (SST). These tumors are therefore suitable candidates for targeted therapy with cytotoxic hybrid molecules consisting of a cytotoxic radical and a peptide hormone analogue as a carrier. These compounds have been shown to be more active and less toxic in vivo than nontargeted chemotherapy in models of various human cancers which express the respective receptors. The current review summarizes experimental and clinical findings with cytotoxic peptide hormone analogues of LHRH (AN-152 [AEZS 108], AN-207), BN/GRP (AN-215), and SST (AN-238) in breast, ovarian, and endometrial cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available